• 1
    Cecka JM. The UNOS Scientific Renal Transplant Registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 2001. Los Angeles , UCLA Immunogenetics Center 2002: 118.
  • 2
    Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001; 38(6 Suppl. 6): S44S50.
  • 3
    Olyaei AJ, De Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384389.
  • 4
    Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, Ferguson RM. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993; 25: 901902.
  • 5
    Kahan BD. for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194202.
  • 6
    MacDonald AS. for the Rapamune Global Study Group. A worldwide, phase III, randomised, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271280.
  • 7
    Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S. for the Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 12131220.
  • 8
    Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 28332836.
  • 9
    Dean PG, Lund WJ, Larson TS et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 15551561.
  • 10
    Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 11
    Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646652.
  • 12
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461470.
  • 13
    Lo A, Egidi MF, Gaber LW et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin-inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004; 77: 12281235.
  • 14
    Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 10701076.
  • 15
    Stallone G, Di Paolo S, Schena A et al. Early withdrawal of cyclosporine improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2004; 77: 162163.
  • 16
    Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953961.
  • 17
    Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 17761785.
  • 18
    Groth CG, Backman L, Morales JM et al. for the Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 10361042.
  • 19
    Artz MA, Boots JM, Ligtenberg G et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 18801888.
  • 20
    Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003; 7: 217222.
  • 21
    Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18(Suppl. 1): i7i11.
  • 22
    Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364370.
  • 23
    Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57: 208211.
  • 24
    Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. Transplantation 1995; 59: 511514.
  • 25
    Gloor JM, Cohen AJ, Lager DJ et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002; 73: 19651968.
  • 26
    Fluckey JD, Dupont-Versteegden EE, Knox M, Gaddy D, Tesch PA, Peterson CA. Insulin facilitation of muscle protein synthesis following resistance exercise in hindlimb-suspended rats is independent of a rapamycin-sensitive pathway. Am J Physiol Endocrinol Metab 2004; 287: E1070E1075.
  • 27
    Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A 2004; 101: 1059010595.
  • 28
    Bodine SC, Stitt TN, Gonzalez M et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 10141019.
  • 29
    Diaz Encarnacion MM, Griffin MD, Slezak JM et al. Correlation of quantitative digital image analysis with glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 2004; 4: 248256.
  • 30
    Chueh SJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression and prognosis. Transplantation 2003; 76: 375382.
  • 31
    Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003; 76: 426429.
  • 32
    Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 11281134.